Clinical outcomes and bleeding events associated with tirofiban combined with intravenous alteplase in acute ischaemic stroke: a retrospective single-center study - Report - MDSpire
Advertisement
Clinical outcomes and bleeding events associated with tirofiban combined with intravenous alteplase in acute ischaemic stroke: a retrospective single-center study
Outcomes and Hemorrhagic Complications of Tirofiban in Conjunction with Intravenous Alteplase for Acute Ischaemic Stroke
Overview
This study evaluates the efficacy and bleeding risk of tirofiban combined with intravenous alteplase in patients with acute ischaemic stroke (AIS). Results indicate that the combination therapy does not significantly increase bleeding complications.
Background
Acute ischaemic stroke (AIS) is a leading cause of disability and mortality, necessitating effective treatment strategies. Intravenous alteplase is a standard therapy for AIS, but its efficacy can be limited by suboptimal recanalization rates. Tirofiban, an antiplatelet agent, has been explored as a potential adjunct to enhance outcomes in AIS treatment.
Data Highlights
Outcome
Combined Group (CG)
Alteplase Group (AG)
NIHSS at 24h
Lower
Higher
Favorable 90-day outcomes (mRS ≤ 2)
Higher
Lower
Total bleeding rate
28.89%
17.78%
Key Findings
NIHSS scores were significantly lower in the CG compared to the AG at multiple time points (p < 0.01).
Post-treatment vascular status was more favorable in the CG (p = 0.030).
Higher rates of favorable 90-day outcomes (mRS ≤ 2) were observed in the CG (p = 0.020).
Total bleeding rate was 28.89% in the CG and 17.78% in the AG, with no significant difference (p = 0.214).
Inflammatory biomarkers (hs-CRP, IL-6, TNF-α) were significantly lower in the CG at day 7 (p < 0.001).
Clinical Implications
The findings indicate that the bleeding risk associated with this combination therapy remains comparable to alteplase alone.
Conclusion
Tirofiban in conjunction with alteplase may not significantly increase hemorrhagic complications.
